. . . . . . . . . . . "Based on data following oral administration of alcaftadine, the carboxylic acid metabolite is primarily eliminated unchanged in the urine."@en . "Alcaftadina"@en . . . . "6,11-Dihydro-11-(1-Methyl-4-piperidinylidene)-5H-iMidazo[2,1-b][3]benzazepine-3-carboxaldehyde"@en . "The elimination half-life of the carboxylic acid metabolite is approximately 2 hours following topical ocular administration."@en . . "Alcaftadine"@en . "Alcaftadinum"@en . " "@en . "For the prevention of itching associated with allergic conjunctivitis."@en . "147084-10-4"@en . . "Vilasta"@en . "Alcaftadine is a H1 histamine receptor antagonist and inhibitor of the release of histamine from mast cells. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated."@en . . . . "Alcaftadine is a H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. This drug was approved in July 2010."@en . . . . . . . . . . . "The protein binding of alcaftadine and the active metabolite are 39.2% and 62.7% respectively."@en . "Lastacaft"@en . . . . . . "# Mahvan TD, Buckley WA, Hornecker JR: Alcaftadine for the prevention of itching associated with allergic conjunctivitis. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1025-32. doi: 10.1345/aph.1Q755. Epub 2012 Jul 17. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/22811343 # Simons FE, Simons KJ: Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011 Dec;128(6):1139-1150.e4. doi: 10.1016/j.jaci.2011.09.005. Epub 2011 Oct 27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/22035879 # Hussar DA, Samuel J: Vilazodone hydrochloride, linagliptin, and alcaftadine. J Am Pharm Assoc (2003). 2011 Jul-Aug;51(4):557-9. doi: 10.1331/JAPhA.2011.11534. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/21752782"@en . . . . . . . . . . "approved"@en .